<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5596">
  <stage>Registered</stage>
  <submitdate>17/09/2011</submitdate>
  <approvaldate>17/09/2011</approvaldate>
  <nctid>NCT01437215</nctid>
  <trial_identification>
    <studytitle>Pilot Study of the Endologix Fenestrated Stent Graft System</studytitle>
    <scientifictitle>Prospective, Multicenter, Single Arm Feasibility and Initial Safety Study of the Endologix Fenestrated Stent Graft System for the Endovascular Repair of Juxtarenal/Pararenal (JAA/PAA) Aneurysms</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CP-0002</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Juxtarenal Aortic Aneurysm</healthcondition>
    <healthcondition>Pararenal Aortic Aneurysm</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Ventana Fenestrated Stent Graft System

Experimental: Fenestrated Endografting - 


Treatment: devices: Ventana Fenestrated Stent Graft System
Endovascular repair of juxtarenal or pararenal aortic aneurysm

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety - Major Adverse Events = all cause death; bowel ischemia; myocardial infarction; paraplegia; renal failure; respiratory complications of stroke; blood loss &gt;1000cc</outcome>
      <timepoint>30 Days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Feasibility - Procedural Success with aortic/fenestrated and renal stent graft patency and absence of Type I/III endoleak or migration</outcome>
      <timepoint>30 Days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety - Major Adverse Events = all cause death; bowel ischemia; myocardial infarction; paraplegia; renal failure; respiratory complications of stroke; blood loss &gt;1000cc</outcome>
      <timepoint>&gt;30 Days to 5 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse Events - All adverse events, whether serious or non-serious</outcome>
      <timepoint>Procedurally to 5 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Distal Blood Flow - Ankle-brachial index measurements</outcome>
      <timepoint>Discharge to 5 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Renal Dysfunction - eGFR reduction &gt;30% from baseline</outcome>
      <timepoint>Discharge to 5 Years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Device Performance - Aortic, fenestrated, and renal stent graft integrity and patency; migration; endoleak; and aneurysm sac morphology</outcome>
      <timepoint>30 Days to 5 Years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Informed consent understood and signed and pt agrees to all follow-up visits;

          -  Abdominal aortic aneurysm with diameter =5cm or =4cm which has increased by 0.5cm or
             more in the past six months

          -  Adequate iliac/femoral access compatible with the required delivery systems

          -  Non-aneurysmal infrarenal aortic neck &lt;15mm in length

          -  Most caudal renal artery to aortoiliac bifurcation length at least 70mm

          -  Proximal non-aneurysmal aortic neck below the SMA with: diameter 18 to 34 mm; length
             at least 15 mm; angle (clock face) &lt;60째 to the aneurysm sac;

          -  Angle &lt;60째 (clock face) between the SMA and celiac artery

          -  Renal arteries both distal to the SMA by 0-35mm, within 30mm of each other axially,
             with 4 to 8mm lumen diameter, and with clockface angle of 90째 to 210째 to each other

          -  Iliac anatomy suitable for commercial bifurcated stent graft;

          -  Minimum 3cm overlap achievable between fenestrated and bifurcated stent grafts</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Life expectancy &lt;1 year as judged by the investigator;

          -  Psychiatric or other condition that may interfere with the study;

          -  Participating in the enrollment or 30-day follow-up phase of another clinical study;

          -  Known allergy to any device component;

          -  Coagulopathy or uncontrolled bleeding disorder;

          -  Contraindication to contrast media or anticoagulants;

          -  Ruptured, leaking, dissecting, or mycotic aneurysm;

          -  Serum creatinine (S-Cr) level &gt;2.0 mg/dL;

          -  Traumatic vascular injury;

          -  Active systemic or localized groin infection;

          -  Connective tissue disease (e.g., Marfan's Syndrome);

          -  Recent (within prior three months) cerebrovascular accident or myocardial infarction;

          -  Prior renal transplant;

          -  Length of either renal artery to be stented &lt;13mm;

          -  Significant occlusive disease or calcification of either renal artery;

          -  An essential accessory renal artery;

          -  Indispensable inferior mesenteric artery;

          -  Untreated aneurysmal disease of the descending thoracic aorta;

          -  Clinically significant mural thrombus circumferentially in the suprarenal segment;

          -  Prior iliac artery stent implanted that may interfere with delivery system
             introduction;

          -  Unsuitable vascular anatomy

          -  Pregnancy (female patient of childbearing potential only)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>15</actualsamplesize>
    <recruitmentstatus>Unknown status</recruitmentstatus>
    <anticipatedlastvisitdate>1/08/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Endologix</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether the Endologix fenestrated stent graft
      system is safe and feasible in the endovascular repair of juxtarenal or pararenal aortic
      aneurysm.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01437215</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>